Pierre Fabre to launch beta blocker hemangioma trials

Pierre Fabre Dermatologie, specialized skincare department of France's Pierre Fabre Laboratories, has launched a set of clinical trials for a  pediatric beta blocker for the treatment of severe infantile hemangioma.

"This is a major discovery that will bring true therapeutic advance to  patients affected by this highly-apparent disease, which can be very  severe and can have a strong impact on their quality of life and that of  their parents," said Jacques Fabre, general manager of the  subsidiary.